Combining GHRP-2 and ipamorelin is not a standard or evidence-backed protocol
and metabolic efficiency studies
Because these pathways dont overlap, researchers studying one typically arent investigating the same mechanism when they study the other a distinction that matters for anyone comparing the two compounds based on keyword searches like aod vs mots c rather than on their actual mechanistic profiles
We recently reported the results from a randomized, placebo-controlled phase 3 study of tesamorelin, a growth hormone-releasing factor (GRF) analogue, which was shown to significantly reduce VAT and improve lipids, without significant effects on glucose over 26 weeks [8]
53 In another more recent study, IV glutathione prevented the increase in oxidative stress markers while oral NAC (N-acetyl cysteine), an amino acid needed to make glutathione, had no effect